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The field of medicinal chemistry is constantly evolving and it is important for medicinal 
chemists to develop the skills and knowledge required to succeed and contribute to the 
advancement of the field. Future Medicinal Chemistry spoke with Simone Pitman (SP), 
Yao-Zhong Xu (YX), Peter Taylor (PT) and Nick Turner (NT) from The Open University 
(OU), which offers an MSc in Medicinal Chemistry. In the interview, they discuss the 
MSc course content, online teaching, the future of medicinal chemistry education 
and The OU’s work towards promoting widening participation. SP is a Qualifications 
Manager in the Science Faculty at The OU. She joined The OU in 1993 and since 1998 
has been involved in the Postgraduate Medicinal Chemistry provision at The OU. YX is 
a Senior Lecturer in Bioorganic Chemistry at The OU. He has been with The OU from 
2001, teaching undergraduate courses of all years and chairing the master’s course 
on medicinal chemistry. PT is a Professor of Organic Chemistry at The OU and has 
been involved with the production and presentation of The OU courses in Science 
and across the university for over 30 years, including medicinal chemistry modules at 
postgraduate level. NT is a Lecturer in Analytical Science at The OU since 2009 and has 
been involved in the production of analytical sciences courses, as well as contributing 
to the presentation of a number of science courses including medicinal chemistry. 
Interview conducted by Hannah Coaker and Kasumi Crews, Commissioning Editors.
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 Q How did you go about designing 
the syllabus for The Open University’s 
medicinal chemistry postgraduate 
qualifications [1]?
SP: In developing the curriculum for these 
qualifications, we worked with experi-
enced colleagues from industry to identify 
what recently appointed medicinal chem-
ists would require as part of their training. 
Although the typical person we had in mind 
was someone who had completed a synthetic 
organic chemistry PhD in the first 5 years 
of their post, it became quite apparent that 
the content was of interest to a much wider 
audience. As drug development and discov-
ery in industry is usually undertaken by a 
multidisciplinary team, it was clear that 
other scientists within that team (e.g., biolo-
gists, biochemists) would also benefit from 
having a good understanding of the medici-
nal chemistry involved. In fact we realized 
that other sectors, such as health profes-
sionals, would also be interested. When 
we designed the curriculum, we therefore 
ensured that it was accessible to any sci-
ence graduate and not just for those with 
synthetic organic chemistry backgrounds or 
chemistry degrees.
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 Q What comprises the core content?
SP: We decided to include the key therapy areas: 
heart disease, cancer, neuropharmacology, infectious 
diseases, inflammation and pain. We felt that it was 
important to give students a good grounding in the 
core concepts to enable them to access those subjects, 
and by using well-selected case studies, provide exam-
ples of how drugs can be developed to target a par-
ticular disease state. It was also really important that 
we developed students’ skills in being able to interro-
gate information from our online library, e-journals 
and databases, so that they were taught to access and 
critically evaluate high-quality, peer-reviewed informa-
tion. The modules have been designed to teach the core 
basics of what they really need to know, but also enable 
students to develop the right transferable skill set, so 
that whatever topic areas they’re working in, or what-
ever drug team they’re working with in the future, they 
are able to research and identify the information that 
they require.
 Q In what way does the changing nature of R&D 
impact the organization of the course and its 
syllabus?
SP: Each year students have to study a core set of mate-
rials as well as additional materials they can read to 
follow a particular area of interest. We regularly update 
those materials with newly published relevant articles 
for students to access from our website. In addition to 
this, our assessment strategy requires students to con-
duct independent literature searches to find the lat-
est developments in particular areas of the course, so 
that we can ensure they are gaining insight into what’s 
going on in those fields now.
 Q What kind of emphasis do you place on 
communication skills in the course?
NT: Communication is incorporated in some of their 
assessments – some of the work the students participate 
in is group work in which they are expected to be able 
to communicate their work, for example by preparing 
a pitch, presentation slides or giving a talk. In addition, 
students may be required to prepare reports on those 
activities and reflect back on what they have done, how 
they have done it and what they could have done bet-
ter. We also use forums where they have to commu-
nicate the science to each other and have discussions, 
and they also use online ‘conferencing’ where they can 
have discussions with their tutors, share presentations 
and resources with other members of staff or other 
members of the group if they are doing group work.
SP: We do group work activities in two steps. The 
first step is guided group work, which involves a tutor 
teaching the students the core skills needed to work in 
a team effectively, and help them to identify the key 
steps they need to undertake to ensure success. We 
then ask that group to reflect on what they have learnt 
and apply those skills in an independent group activity 
in which they have to organize themselves, undertake 
the research and develop a proposal for a drug, which 
they present to an assessor. At each stage the students 
are encouraged to reflect on what is really at the heart 
of communication in the team, and how they need to 
implement that to ensure that that team reaches its 
objective successfully.
 Q The use of online training and teaching 
materials is becoming increasingly common. Do 
you think that this method of teaching lends 
itself well to medicinal chemistry?
PT: I don’t think there is any problem at all in teaching 
medicinal chemistry either face-to-face or through dis-
tance teaching – each has their own strengths. There 
are lots of other challenges in teaching medicinal 
chemistry generally, but I don’t see online teaching as 
being a real issue. One of the great strengths of online 
teaching is the ability to be able to develop accessible 
online materials, such as having an online library where 
students can go and find articles. I think there are real 
opportunities with distance teaching: you don’t need 
to go to a particular place to study and you don’t have 
to do it at a particular time. If you’re working, then 
that’s a real bonus because from a company’s point of 
view, they don’t have to give days off to individuals for 
training. They can help students study by paying for 
the course, but the student studies in their own time.
SP: This means that there is no loss of productiv-
ity from that member of staff. They carry on work-
ing while improving their skills and expanding their 
knowledge, which helps them in their career. In large 
pharmaceutical companies, it is also particularly attrac-
tive to be able to offer the same training opportunities 
for staff based in the UK, Europe, Asia or anywhere 
else in the world.
YX: With the wide use of the internet, accessing 
knowledge is no longer a big issue. However, how to 
make good use of knowledge remains an important 
key skill.
 Q How does the online training aspect translate 
for the practical side of medicinal chemistry?
SP: Our focus is on theory and transferable skills 
development, therefore we don’t do any practical work 
per se. There are some simulations and molecular 
modeling that students incorporate into their group 
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work or project work, however those working in 
industry will be developing bench skills in their work-
place. In our discussions with industry, we found that 
practical work wasn’t where the need for improving 
knowledge and understanding really was. They were 
more concerned with ensuring chemists understood 
medicinal chemistry elements of projects, and learnt 
how to design potential drug molecules and ensure 
they could be successful molecules further down the 
production line.
 Q In the future, do you think that medicinal 
chemistry students will be ‘programmed’ onto 
career paths earlier in order to maximize their 
lifetime output?
SP: I’m not convinced they will. I think the nature of 
the pharmaceutical industry has really changed over 
the last 5 years and there is much more flexibility in 
how research operates now. I think the emphasis is 
shifting onto the individual to take more responsi-
bility for their own training and their own learning. 
Small biotechs can be quite transient – it’s becoming 
quite common for people to work for 3 or 5 years and 
then move onto another project in another company. 
Medicinal chemists therefore need to ensure that their 
skillset and their knowledge are up to date so they are 
an attractive proposition to the next company that they 
want to work for.
NT: A lot of science in the medicinal chemistry and 
the pharmaceutical sector is becoming more interdisci-
plinary, so it is becoming more important to have peo-
ple with an understanding of how chemistry, biology 
and analytical science all fit together rather than hav-
ing someone who’s a particular type of organic chemist 
or biologist.
 Q What future do you see for partnering 
between the pharmaceutical industry and 
universities?
SP: I am sure there will be more of this in terms of the 
training opportunities. We are already seeing that hap-
pening in R&D. Certainly over the last 5 years, there 
are far more initiatives where industry is collaborating 
with universities and with other companies, so I’m sure 
that will seep down through to the degrees and post 
graduate offerings that are available.
PT: For small and medium industries it is financially 
very difficult to support their own in-house educa-
tion, therefore it becomes sensible for them to partner 
with local education establishments to develop some of 
those skills in their staff. Studying with The OU, one 
clear benefit is that staff study in their own time so do 
not need days off. Also, our medicinal chemistry mas-
ters was designed to be delivered globally to potential 
students anywhere in the world, and as the industry 
becomes more global, it becomes necessary to train a 
global workforce rather than just a local workforce.
 Q Do you think there is a danger that courses 
run in partnership between companies and 
universities would limit medicinal chemists into 
working for those particular companies?
SP: I don’t think so. Medicinal chemists need to ensure 
they have a good grounding and good understanding 
of the core subjects. The skill set they develop and 
their flexibility provide them with a good grounding 
for any career that they go into. Industry want staff 
that are flexible and are able to move from one project 
to another and from one area of science to another. To 
have that skill set, you need to be able to interrogate 
information successfully rather than just narrowly 
focussing on one particular project that you happen to 
have the need for now.
YX: The skills developed in our modules are trans-
ferable: critical thinking, evaluation of literature, the 
ability to present results to the scientific community 
(via posters and presentations) and write review articles 
for publication are valued across the whole sector.
 Q Aside from entering the pharmaceutical 
sector, where there is a declining number of job 
opportunities, what other career options are 
available to medicinal chemistry students? What 
have your past students gone on to do?
PT: From a chemistry perspective, what’s interest-
ing is the number of people that go into chemistry-
related work and the number of people who use the 
wide range of skills developed in a whole range of 
other career areas. It’s the same in medicinal chem-
istry – there will be a number of people who train in 
medicinal chemistry and use those skills at the bench 
as medicinal chemists, but may move onto other areas 
such as management, marketing and patents, where 
having medicinal chemistry expertise is important. As 
well as the medicinal chemistry masters programme, 
there is a professional science masters at The OU, 
which involves one of the medicinal chemistry mod-
ules and another 60 credit module called ‘strategic 
management in life sciences and healthcare’, which 
is more focused on the business around the phar-
maceutical industry. In this module, students learn 
about the shape of the industry, the strategic choices, 
finance, scenario planning and other aspects that are 
important to medicinal chemists as they move on to 
manage businesses. Some of my students who have 
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been on the course have gone off to work in clinical 
trials management and other areas of assurance, so I 
don’t think there is a single career path for medicinal 
chemists.
YX: Our past students are now working in a wide 
range of professions including university academics, 
school teachers, researchers and technicians.
SP: We have quite a broad range of students. Many 
come from the pharmaceutical industry and small bio-
technology companies to broaden their understanding 
in medicinal chemistry. Others will be science gradu-
ates who want to understand the drug-discovery pro-
cess, or those working in healthcare sectors – we have 
medics and nurses that take the module. We have had 
a few students take modules within the masters to 
support entry into graduate medicine.
 Q Do you think the needs of those already 
working in the field of medicinal chemistry are 
being met in terms of continuing professional 
development opportunities?
SP: I think the continuing professional development 
market is moving away from the traditional model of 
large pharmaceutical companies having all their training 
in-house. The way companies are being structured and 
smaller biotechs taking a product so far and then being 
bought out has meant that medicinal chemists move 
around from company to company much more so than 
they have done previously. Industry is also mindful that 
they have invested in staff development, only to lose staff 
to other companies. There has been a shift and medici-
nal chemists are now taking more personal responsibility 
for their own career development and becoming more 
proactive about managing their own training to ensure 
that they are keeping up to date, rather than leaving it to 
internal career appraisals from their line managers to tell 
them they need some training. This will sometimes be in 
partnership with their employer, and other times if they 
feel they have missed out on a chance to do training, 
they will do it themselves.
The growth of Massive Open Online Courses is 
an interesting development – so far some of them are 
excellent, but others are not. They are very difficult to 
quantify as they don’t provide students with any sort of 
badge other than completion, and there is no currency 
or recognition for them yet.
PT: Massive Open Online Courses are problematic to 
evaluate because it is difficult to assess how much the 
student has engaged with the content, and whether 
they have actually benefited or put the work in to 
develop themselves.
 Q Why do you think people are adopting a more 
proactive approach to their own training and self 
development?
SP: I think this is due to the more transient nature of 
the industry. When people first enter the workforce at 
25 after a PhD, they don’t tend to stay in the same 
company until they retire. People tend to move around 
projects and companies so I think that’s the reason why 
they need to take a much more proactive approach. 
This is particularly true for the SME part of the sec-
tor where companies may only survive 3–5 years if it’s 
moved its products onto the point where it’s become 
a very attractive acquisition for a bigger company, for 
example. At that point, people may be looking for 
another job or they may want to move around for per-
sonal reasons. Having a CV that demonstrates they’re 
well qualified, keep up to date and are proactive in tak-
ing responsibility for their training is very attractive to 
an employer.
 Q One of The OU’s missions is to promote equal 
opportunities for all: what measures are you 
taking to widen the reach of the course?
SP: These particular Medicinal Chemistry qualifica-
tions are available completely online. Previously, there 
was a requirement for students to come to a day school 
in Milton Keynes (UK), which wasn’t always easy 
for everyone. By putting it all online, where we have 
online synchronous and asynchronous sessions where 
students interact, anybody anywhere can join in. The 
opportunity to be able to study when you want and 
where you want makes it more accessible to people 
who are unable to travel or study at particular times, 
especially those balancing other commitments or those 
with disabilities. The OU is the largest provider of 
higher education for people with disabilities.
PT: We also thought about the fact that students 
would be studying globally. When I was giving an 
online tutorial to my project group the other day, there 
were people joining me from Vancouver, Belgium and 
Spain. There are some diseases that are very Western 
and others that are much more global. We tried to give 
a balance of diseases which aren’t just EU- or America-
centric, but reflect a more global need of medicinal 
chemistry. For example, in one of the modules we have 
a case study on malaria, which is much more prevalent 
in the developing world.
 Q What is The OU doing to improve the 
representation of women in science?
SP: We have a high proportion of female students 
studying with us, partly because distance learning 
enables them to study whilst balancing other fam-
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ily responsibilities or their work. The OU has been 
involved in a broad number of projects for the last 20 
years or more that have enabled women to either get 
back into STEM working or STEM training.
PT: We are also careful in the language we use in terms 
of the teaching representations and examples of indi-
viduals to ensure there is a reasonable distribution of 
gender and ethnicity.
 Q Professor of Education at The OU, Bob Moon, 
has played a key role in lobbying for improved 
education in the developing world. What 
progress has The OU made towards addressing 
this issue?
SP: The OU has a very wide range of international 
projects, as part of its social mission to make the great-
est use of its educational content. For example, one is 
the Teacher Education in Sub-Saharan Africa project, 
which aims to improve the quality and provision of 
teaching across Africa. Another is Health Education 
and Training, which focuses on healthcare workers in 
Africa. The impact of these projects has been enor-
mous – they have trained over half a million teach-
ers and health workers. Some of this work is being 
expanded into Asia, with projects in Bangladesh, India 
and Pakistan.
PT: Some of the work in which I have personally been 
involved is developing an e-learning capacity at the 
University of Delhi so that they can take in a larger 
number of students from a range of backgrounds. More 
recently I have been working on a European funded 
project which involved developing an e-learning capac-
ity at universities in central Asia (Uzbekistan and 
Kazakhstan). There are a lot of projects going on and 
there are a lot of opportunities for development work.
 Q What words of advice do you have for an 
aspiring medicinal chemist?
PT: My advice is quite simple: don’t forget your chem-
istry skills. Chemists, and in particular medicinal 
chemists, are trained for thinking in various ways to 
problem solve, to be reasonably numeric and to think 
about structures of materials at a molecular level. 
Those are the key things that I think we can really pro-
vide to the pharmaceutical area. I think chemists are 
naturally creative and chemistry is one of the few cre-
ative subjects there are. My PhD students can go into 
the laboratory and create a compound that’s never been 
made before. It’s important to remember that you’re 
bringing those qualities to the team of people that is 
tackling a particular problem.
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